New findings presented at ESTRO 2026 in Stockholm reported that a prostate cancer radiotherapy regimen delivered in two larger sessions over eight days can be as safe and effective as the conventional five-fraction schedule, without additional side effects. The study supports the feasibility of hypofractionated approaches that compress treatment burden. For health systems, fewer sessions can reduce logistical friction and patient travel while maintaining clinical outcomes—an issue that becomes more acute as capacity strains. Clinicians will likely look for clarity on which patient subgroups are best suited to the abbreviated regimen. The data adds to the expanding evidence base supporting shortened radiation courses in localized disease management.